Early-Stage ER/PR–Positive, HER2-Negative Breast Cancer

William J. Gradishar*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter provides answers to practice-based questions with case studies covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of early-stage estrogen receptor (ER)/progesterone receptor–positive, HER2-negative breast cancer. Adjuvant endocrine therapy of early stage, hormone sensitive breast cancer continues to evolve with unanswered questions regarding the optimal duration of both tamoxifen and aromatase inhibitors as well as integration of newer targeted therapies for those with high risk disease. These questions remain germane because ER–positive breast cancer has an ongoing risk of recurrence 20 years after the original diagnosis, with a greater absolute risk for late recurrence especially for those with higher risk features at diagnosis.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise in Clinical Practice, Volume 1: Solid Tumors and Supportive Care
Publisherwiley
Pages129-138
Number of pages10
Volume1
ISBN (Electronic)9781119823766
ISBN (Print)9781119823735
DOIs
StatePublished - Jan 1 2023

Keywords

  • Endocrine therapy
  • ER–positive breast cancer
  • HER2-negative breast cancer
  • Hormone sensitive breast cancer
  • Progesterone receptor–positive breast cancer

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Early-Stage ER/PR–Positive, HER2-Negative Breast Cancer'. Together they form a unique fingerprint.

Cite this